SCHAUMBURG, Ill., Oct. 27, 2015 (GLOBE NEWSWIRE) -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) today announced the launch of Chlorothiazide Sodium for Injection, USP, a diuretic/antihypertensive agent, in a 500 mg preservative-free, single-dose vial. According to IMS, for the 12 months ending August 2015, the US market for Chlorothiazide approximated $29 million. As with all products in Sagent's portfolio, Chlorothiazide features Sagent’s PreventIV MeasuresSM Packaging and Labeling, designed to help reduce the risk of medication errors.
About Chlorothiazide Sodium for Injection, USP
Chlorothiazide Sodium for Injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide Sodium for Injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.
The package insert, available at www.SagentPharma.com, contains the indications, complete side effect profile and prescribing information.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 email@example.com
Source:Sagent Pharmaceuticals, Inc.